AU2022402390A1 - Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer - Google Patents
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer Download PDFInfo
- Publication number
- AU2022402390A1 AU2022402390A1 AU2022402390A AU2022402390A AU2022402390A1 AU 2022402390 A1 AU2022402390 A1 AU 2022402390A1 AU 2022402390 A AU2022402390 A AU 2022402390A AU 2022402390 A AU2022402390 A AU 2022402390A AU 2022402390 A1 AU2022402390 A1 AU 2022402390A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- equiv
- mmol
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284778P | 2021-12-01 | 2021-12-01 | |
| US202163284754P | 2021-12-01 | 2021-12-01 | |
| US63/284,754 | 2021-12-01 | ||
| US63/284,778 | 2021-12-01 | ||
| PCT/EP2022/083954 WO2023099624A1 (en) | 2021-12-01 | 2022-11-30 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022402390A1 true AU2022402390A1 (en) | 2024-05-30 |
Family
ID=84536046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022402390A Pending AU2022402390A1 (en) | 2021-12-01 | 2022-11-30 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12060367B2 (https=) |
| EP (1) | EP4441055A1 (https=) |
| JP (1) | JP2024543967A (https=) |
| KR (1) | KR20240128852A (https=) |
| CN (1) | CN119841847A (https=) |
| AU (1) | AU2022402390A1 (https=) |
| CA (1) | CA3240980A1 (https=) |
| CL (1) | CL2024001617A1 (https=) |
| CO (1) | CO2024007014A2 (https=) |
| CR (1) | CR20240233A (https=) |
| DO (1) | DOP2024000101A (https=) |
| IL (1) | IL312905A (https=) |
| JO (1) | JOP20240124A1 (https=) |
| MX (1) | MX2024006681A (https=) |
| PE (1) | PE20241356A1 (https=) |
| TW (1) | TW202337431A (https=) |
| WO (1) | WO2023099624A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| JP2025537366A (ja) | 2022-11-30 | 2025-11-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スピロ環状ｋｒａｓ阻害剤の調製のためのプロセス及び中間体 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2024246099A1 (en) * | 2023-05-30 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2024255795A1 (en) * | 2023-06-14 | 2024-12-19 | Insilico Medicine Ip Limited | Kras inhibitors and uses thereof |
| WO2025016899A1 (en) | 2023-07-19 | 2025-01-23 | Bayer Aktiengesellschaft | Spirocyclic compounds for the treatment of cancer |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| CN117946135A (zh) * | 2024-01-24 | 2024-04-30 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| CN117924327A (zh) * | 2024-01-24 | 2024-04-26 | 上海湃隆生物科技有限公司 | 具有大环结构的Kras抑制剂化合物 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025190158A1 (zh) * | 2024-03-14 | 2025-09-18 | 四川科伦博泰生物医药股份有限公司 | 螺环化合物、其制备方法及用途 |
| WO2025190342A1 (zh) * | 2024-03-15 | 2025-09-18 | 苏州浦合医药科技有限公司 | 螺环化合物作为kras突变体抑制剂 |
| WO2025201480A1 (zh) * | 2024-03-28 | 2025-10-02 | 苏州浦合医药科技有限公司 | 螺环化合物作为kras突变体抑制剂 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025261393A1 (en) * | 2024-06-19 | 2025-12-26 | Insilico Medicine Ip Limited | Novel compounds as kras inhibitors and uses thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026007740A1 (zh) * | 2024-07-04 | 2026-01-08 | 四川科伦博泰生物医药股份有限公司 | 螺环化合物、其制备方法及用途 |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119330881A (zh) * | 2024-09-06 | 2025-01-21 | 苏州汉德创宏生化科技有限公司 | 一种3-氨甲基-1-h吡唑的合成方法 |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597692A (en) | 2008-12-12 | 2013-08-30 | Boehringer Ingelheim Int | Anti-IGF antibodies |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| NZ629432A (en) | 2012-03-14 | 2017-01-27 | Lupin Ltd | Heterocyclyl compounds as mek inhibitors |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP3055290B1 (en) | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| WO2015155332A1 (en) | 2014-04-11 | 2015-10-15 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors |
| WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| RS59111B1 (sr) | 2014-08-21 | 2019-09-30 | Boehringer Ingelheim Int | Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori |
| KR20240158360A (ko) | 2015-10-09 | 2024-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체 |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| CA3081983A1 (en) | 2016-11-30 | 2018-06-07 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018172250A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| WO2018204532A1 (en) | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| HRP20230400T1 (hr) | 2017-12-21 | 2023-06-23 | Boehringer Ingelheim International Gmbh | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| MX2021000887A (es) * | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| MX2021010319A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos biciclicos de heteroarilo y usos de estos. |
| MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
| WO2020177629A1 (zh) | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| JP7502337B2 (ja) | 2019-05-20 | 2024-06-18 | カリフォルニア インスティチュート オブ テクノロジー | Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| PT3886991T (pt) * | 2019-12-11 | 2022-10-17 | Lilly Co Eli | Inibidores de kras g12c |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| WO2021139748A1 (en) | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| UY39129A (es) | 2020-03-16 | 2021-10-29 | Novartis Ag | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead |
| CN113683616B (zh) | 2020-05-18 | 2025-12-30 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
| JP7808058B2 (ja) | 2020-06-02 | 2026-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
| JP2024543976A (ja) | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| WO2023099608A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| JP2024542692A (ja) | 2021-12-01 | 2024-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 環化２－アミノ－３－シアノチオフェンを含むｋｒａ分解化合物 |
| TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| US20230227470A1 (en) * | 2021-12-01 | 2023-07-20 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118574835A (zh) | 2021-12-01 | 2024-08-30 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
-
2022
- 2022-11-30 WO PCT/EP2022/083954 patent/WO2023099624A1/en not_active Ceased
- 2022-11-30 JP JP2024532457A patent/JP2024543967A/ja active Pending
- 2022-11-30 IL IL312905A patent/IL312905A/en unknown
- 2022-11-30 TW TW111145888A patent/TW202337431A/zh unknown
- 2022-11-30 MX MX2024006681A patent/MX2024006681A/es unknown
- 2022-11-30 CR CR20240233A patent/CR20240233A/es unknown
- 2022-11-30 PE PE2024001288A patent/PE20241356A1/es unknown
- 2022-11-30 AU AU2022402390A patent/AU2022402390A1/en active Pending
- 2022-11-30 EP EP22823522.2A patent/EP4441055A1/en active Pending
- 2022-11-30 KR KR1020247021664A patent/KR20240128852A/ko active Pending
- 2022-11-30 CN CN202411691317.4A patent/CN119841847A/zh active Pending
- 2022-11-30 CA CA3240980A patent/CA3240980A1/en active Pending
-
2023
- 2023-05-09 US US18/314,445 patent/US12060367B2/en active Active
-
2024
- 2024-05-24 DO DO2024000101A patent/DOP2024000101A/es unknown
- 2024-05-30 JO JOJO/P/2024/0124A patent/JOP20240124A1/ar unknown
- 2024-05-30 CL CL2024001617A patent/CL2024001617A1/es unknown
- 2024-05-31 CO CONC2024/0007014A patent/CO2024007014A2/es unknown
- 2024-06-26 US US18/755,002 patent/US20250002504A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240233A (es) | 2024-07-17 |
| PE20241356A1 (es) | 2024-07-03 |
| WO2023099624A1 (en) | 2023-06-08 |
| EP4441055A1 (en) | 2024-10-09 |
| IL312905A (en) | 2024-07-01 |
| MX2024006681A (es) | 2024-08-26 |
| CO2024007014A2 (es) | 2024-07-29 |
| TW202337431A (zh) | 2023-10-01 |
| US12060367B2 (en) | 2024-08-13 |
| CA3240980A1 (en) | 2023-06-08 |
| KR20240128852A (ko) | 2024-08-27 |
| JOP20240124A1 (ar) | 2024-05-30 |
| US20250002504A1 (en) | 2025-01-02 |
| US20240174690A1 (en) | 2024-05-30 |
| CL2024001617A1 (es) | 2024-12-20 |
| DOP2024000101A (es) | 2024-08-15 |
| JP2024543967A (ja) | 2024-11-26 |
| CN119841847A (zh) | 2025-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12545670B2 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| EP4441055A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| WO2023099608A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| WO2023099623A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| WO2023099592A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| US20250296940A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| US20250019385A1 (en) | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| CA3085835A1 (en) | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| HK40097417A (en) | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| HK40039222A (en) | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| HK40039222B (en) | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |